Paraoxonase 1 (PON1) promotes antioxidant and antiatherogenic activity related to the hydrolysis of oxidized lipids of low-density lipoproteins. In rheumatoid arthritis (RA) patients, it has been reported that low PON1 activity is related to an impaired lipid profile, increasing cardiovascular risk (CVR). The goal of this study was to analyze the effect of common PON1 polymorphisms and haplotypes on enzymatic activity, PON1 serum levels (PON1s), and lipid parameters related to atherogenic profile in RA patients.
A cross-sectional study was carried out on 250 Mexican patients with RA. The lipid profile was determined by colorimetric tests. The PON1 activity (CMPAase) was measured by spectrophotometry. The levels of PON1s were determined by ELISA, and the polymorphisms in the PON-1 gene (-108C>T, L55M, and Q192R) were genotyped by the PCR-RFLP method. The haplotypes were estimated and statistical analysis was performed.
The median of the CMPAase activity and PON1 levels was 13.91 U/mL and 24.75 ng/mL, respectively. The CMPAase activity was significantly lower in carriers of -108TT and 192QQ genotypes (β = − 4.09, P = 0.001 and β = − 3.73, P = 0.002, respectively); moreover, the PON1 levels were lower in 192Q allele carriers (P < 0.01). The TLQ haplotype was associated with CMPAase activity < 13.91 U/mL (OR = 2.29, P < 0.001), as well as with levels of PON1s < 24.75 ng/mL (OR = 1.65, P = 0.017). In this study, the CMPAase activity (< 13.91 U/mL) showed a positive association with lower levels of high-density lipoprotein cholesterol (HDL-c; < 40/50 mg/dL), and with a triglycerides/HDL-c ratio > 3%, and a total cholesterol/HDL-c ratio > 4.5/5%, all representatives of an atherogenic risk lipid profile.
PON1 polymorphisms modulate the CMPAase activity and PON1 levels in Mexican patients with RA. The CMPAase activity < 13.91 U/mL is associated with an atherogenic lipid profile, independently of inflammation markers and treatment with anti-rheumatic drugs.
•The haplotype TLQ is a marker for low PONase activity in rheumatoid arthritis.
•The haplotype TLQ is a marker for low PON1 serum levels in rheumatoid arthritis.
•The enzymatic PON1 activity represents the best marker for an atherogenic lipid profile in rheumatoid arthritis, in comparison with PON1 levels.
•The haplotype TLQ is a marker of low PON1 activity, levels of PON1s, and atherogenic lipid profile, independent of treatment therapy in rheumatoid arthritis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Litvinov D, Mahini H, Garelnabi M (2012) Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 4:523–532
Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498–507
Mackness B, Durrington PN, Mackness MI (1998a) Human serum paraoxonase. Gen Pharmac 31:329–336
Bergmeier C, Siekmeier R, Gross W (2004) Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 50:2309–2315
Mackness MI, Arrol S, Durrington PN (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152–154
Mackness MI, Mackness B, Durrington PN (1998c) Paraoxonase and coronary heart disease. Curr Opin Lipidol 9:319–324
Gupta N, Gill K, Singh S (2009) Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J Med Res 130:361–368
Mackness M, Mackness B (2015) Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene 567:12–21
Leviev I, Deakin S, James RW (2001) Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 42:528–535
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1997) Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122:265–268
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998b) Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57–60
Shahmohamadnejad S, Vaisi-Raygani A, Shakiba Y, Kiani A, Rahimi Z, Bahrehmand F, Shakiba E, Pourmotabbed T (2015) Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: correlation with systemic inflammatory markers and oxidative stress, preliminary report. Clin Biochem 48:63–69
Charles-Schoeman C, Lee YY, Shahbazian A, Gorn AH, FitzGerald J, Ranganath VK, Taylor M, Ragavendra N, McMahon M, Elashoff D, Reddy ST (2013) Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. Arthritis Rheum 65:2765–2772
Pérez-Herrera N, May-Pech C, Hernández-Ochoa I, Castro-Mañé J, Rojas-García E, Borja-Aburto VH, Castillo-Burguete T, Quintanilla-Vega B (2008) PON1Q192R polymorphism is associated with lipid profile in Mexican men with Mayan ascendancy. Exp Mol Pathol 85:129–134
Moreno-Godínez ME, Galarce-Sosa C, Cahua-Pablo JÁ, Rojas-García AE, Huerta-Beristain G, Alarcón-Romero LC, Cruz M, Valladares-Salgado A, Antonio-Véjar V, Ramírez-Vargas MA, Flores-Alfaro E (2018) Genotypes of common polymorphisms in the PON1 gene associated with paraoxonase activity as cardiovascular risk factor. Arch Med Res 49:486–496
Huesca-Gómez C, Soto ME, Castrejón-Téllez V, Pérez-Méndez O, Gamboa R (2013) PON1 gene polymorphisms and plasma PON1 activities in Takayasu’s arteritis disease. Immunol Lett 152:77–82
Tanhapour M, Shahmohamadnejad S, Vaisi-Raygani A, Kiani A, Shakiba Y, Rahimi Z, Bahrehmand F, Shakiba E, Vaisi-Raygani AA, Alibakhshi R, Eivazi A, Pourmotabbed T (2019) Association between activity and genotypes of paraoxonase1 L55M (rs854560) increases the disease activity of rheumatoid arthritis through oxidative stress. Mol Biol Rep 46:741–749
Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K, Hashimoto K (2003) Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 72:2877–2885
Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, Muhtaroglu S (2005) Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 38:951–955
Isik A, Koca SS, Ustundag B, Celik H, Yildirim A (2007) Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 26:342–348
Krougly LB, Fomicheva OA, Karpov YA, Popkova TV, Novikova DS, Nasonov EL (2016) Cardiovascular complications of rheumatoid arthritis: prevalence and pathogenesis. Kardiologiia 56:89–95
Van den Hoek J, Boshuizen HC, RoordaLD, et al (2017) Mortality in patients with rheumatoid arthritis: a 15 years a prospective cohort study. Rheumatol Int 37:487–493
Cho SK, Kim D, Won S et al (2017) Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis. Semin Arthiritis Rheum 47:501–506
Dilek E, Polat MF (2016) In vitro inhibition of three different drugs used in rheumatoid arthritis treatment on human serum paraoxanase 1 enzyme activity. Protein Pept Lett 23:3–8
Isgör MM, Beydemir S (2010) Some cardiovascular therapeutics inhibit paraoxonase 1 (PON1) from human serum. Eur J Pharmacol 645:135–142
Ekinci D, Beydemir S (2009) Effect of some analgesics on paraoxonase-1 purified from human serum. J Enzyme Inhib Med Chem 24:1034–1039
Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell’Italia LJ, Moreland LW, O’Dell JR, Paulus HE, Curtis JR (2013) Changes in lipoproteins associated with treatment with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheumatoid 65:1430–1438
Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millán I, Yang S, Chen L, Cofield SS, Moreland LW, O’Dell J, Bathon JM, Paulus H, Louis Bridges S Jr, Curtis JR (2016) Association of triple therapy with improvement in cholesterol profiles over two years follow-up in the treatment of early aggressive rheumatoid trial. Arthritis Rheumatol 68:577–586
Charles-Schoeman C, Lee YY, Shahbazian A (2017) Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheumatol 69:46–57
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugue. Clin Chem 18:499–502
Grundy SM, Cleeman JI, Daniels SR (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit Pathw Cardiol 4:198–203
López-González AA, Rivero-Ledo YI, Vicente-Herrero MT et al (2015) Índices aterogénicos en trabajadores de diferentes sectores laborales del área mediterránea española. Clin Invest Arterioscl 27:118–128
Rodríguez-Carrio J, Alperi-López M, López P et al (2017) High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: a potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein. J Clin Lipidol 11:1043–1054.e2
Wakabayashi I, Daimon T (2015) The “cardiometabolic index” as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta 438:274–278
Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ (2010) The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring) 18:1836–1844
Richter RJ, Jarvik GP, Furlong CE (2008) Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 1:147–152
Bernal-Hernández YY, Medina-Díaz IM, Barrón-Vivanco BS, Robledo-Marenco ML, Girón-Pérez MI, Pérez-Herrera NE, Quintanilla-Vega B, Cerda-Flores R, Rojas-García AE (2014) Paraoxonase 1 and its relationship with pesticide biomarkers in indigenous Mexican farmworkers. J Occup Environ Med 56:281–290
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE (2001) Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77–84
Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, Castaldo M, Bitto A, Cinquegrani M, Saitta A (2005) Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin 21:777–784
Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97–98
El-Banna H, Jiman-Fatani A (2014) Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis. BMC Musculoskelet Disord 15:379
Gamboa R, Regalado JC, Huesca-Gómez C, Posadas-Romero C, Verdejo Paris J, Vargas-Alarcón G, Pérez-Méndez O (2008) Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease. Arch Cardiol Mex 78:360–368
Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD (2011b) Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in north-west Indian Punjabis. PLoS One 6:e17805
Bae SC, Lee YH (2019) Association between paraoxonase 1 (PON1) polymorphism and susceptibility and PON1 activity in rheumatoid arthritis patients, and comparison of PON1 activity in patients and controls: a meta-analysis. Clin Rheumatol 38:2141–2149
Mucientes A, Fernández-Gutiérrez B, Herranz E, Rodriguez-Rodriguez L, Varadé J, Urcelay E, Lamas JR (2019) Functional implications of single nucleotide polymorphism rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis. Clin Rheumatol 38:1329–1337
Fridman O, Gariglio L, Riviere S, Porcile R, Fuchs A, Potenzoni M (2016) Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia. Arch Cardiol Mex 86:350–357
Singh K, Singh R, Chandra S, Tyagi S (2018) Paraoxonase-1 is a better indicator than HDL of atherosclerosis-a pilot study in north Indian population. Diabetes Metab Syndr 12:275–278
González FEM, Ponce-Ruíz N, Rojas-García AE et al (2019) PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers. Arch Med Sci Atheroscler Dis 4:e47–e54
Bielicki JK, Forte TM, McCall MR (1996) Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity. J Lipid Res 37:1012–1021
Ly H, Francone OL, Fielding CJ, Shigenaga JK, Moser AH, Grunfeld C, Feingold KR (1995) Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res 36:1254–1263
Gómez-Rosso L, Lhomme M, Meroño T et al (2014) Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. Atherosclerosis 237:652–660
Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A (2006) Reciprocal and coordinate regulation of serum amyloid a versus apolipoprotein a-1 and paraoxonase 1 by inflammation in murine hepatocytes. Arterioscler. Thromb. Vasc Biol 26:1806–1813
Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X, Furst DE, Ranganath VK, Maldonado M, Lee T, Reddy ST (2018) Remodeling of the HDL proteome with treatment response to abatecept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Atherosclerosis 275:107–114
McDaniel CY, Dail MB, Wills RW, Chambers HW, Chambers JE (2014) Paraoxonase 1 polymorphisms within a Mississippi USA population as possible biomarkers of enzyme activities associated with disease susceptibility. Biochem Genet 52:509–523
Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojo IE et al (2016) Effects of paraoxonase 1 gene polymorphism on hearth diseases: systematic review and meta-analysis of 64 case-control studies. Medicine (Baltimore) 95:e5298
Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM, Ghavami S (2010a) Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res 9:333–339
Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Taheri M, Bardestani GR, Zakeri Z, Kordi-Tamandani DM, Ghavami S (2010b) The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 9:1735–1741
Khoja SO, Miedany YE, Iyer AP, Bahlas SM, Balamash KS, Elshal MF (2017) Association of paraoxonase 1 polymorphism and serum 25-hydroxyvitamin D with the risk of cardiovascular disease in patients with rheumatoid arthritis. Clin Lab 63:1841–1849
Elfasakhany FM, Abou-Enoeman SA, Hussein ME, Lamfoon HA, Beyari MM (2014) Paraoxonase activity and gene polymorphism in rheumatoid arthritis among Egyptians. Clin Med Diagn 4:15–20
López-Mejías R, Genre F, Corrales A, González-Juanatey C, Ubilla B, Llorca J, Miranda-Filloy JA, Pina T, Blanco R, Castañeda S, Martín J, González-Gay MA (2014) Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 73:1749–1750
Rodríguez-Carrio J, López-Mejías R, Alperi-López M, López P, Ballina-García FJ, González-Gay MÁ, Suárez A (2016) Paraoxonase 1 activity is modulated by the rs662 polymorphism and IgG anti-high-density lipoprotein antibodies in patients with rheumatoid arthritis: potential implications for cardiovascular disease. Arthritis Rheumatol 68:1367–1376
Moreno-Estrada A, Gignoux CR, Fernández-López JC et al (2014) The genetics of Mexico recapitulates Native American substructure and affects biomedical trials. Science 344:1280–1285
Gupta N, Binukumar BK, Singh S, Sunkaria A, Kandimalla R, Bhansali A, Gill KD (2011a) Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a north-west Indian population. Gene 487:88–95
Ahmad I, Narang R, Venkatraman A, Das N (2012) Two-and three-locus haplotypes of the paraoxonase (PON1) gene are associated with coronary artery disease in Asian Indians. Gene 506:242–247
Special thanks to the patients for allowing us to use them as subjects to investigate in the study. Also, thanks go to the group of collaborators in the multidisciplinary team who contributed their knowledge and support for the management of an integral approach to these patients.
Confidentiality of the data
The authors declare that they have followed the protocols of their work center on the publication of patient data.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki Declaration.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zaragoza-García, O., Guzmán-Guzmán, I.P., Moreno-Godínez, M.E. et al. PON-1 haplotype (-108C>T, L55M, and Q192R) modulates the serum levels and activity PONase promoting an atherogenic lipid profile in rheumatoid arthritis patients. Clin Rheumatol 40, 741–752 (2021). https://doi.org/10.1007/s10067-020-05218-w
- CMPAase activity
- PON1 polymorphisms
- PON1 levels
- Rheumatoid arthritis